Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 04:00PM ET
0.4335
Dollar change
-0.0242
Percentage change
-5.29
%
Index- P/E- EPS (ttm)-0.96 Insider Own15.78% Shs Outstand40.81M Perf Week12.04%
Market Cap18.01M Forward P/E- EPS next Y-0.75 Insider Trans0.00% Shs Float34.99M Perf Month-14.16%
Income-34.27M PEG- EPS next Q-0.19 Inst Own10.36% Short Float2.07% Perf Quarter-28.67%
Sales0.00M P/S- EPS this Y-0.81% Inst Trans-22.12% Short Ratio0.50 Perf Half Y-79.06%
Book/sh0.35 P/B1.22 EPS next Y13.06% ROA-103.30% Short Interest0.72M Perf Year-73.89%
Cash/sh0.53 P/C0.82 EPS next 5Y- ROE-157.90% 52W Range0.34 - 2.95 Perf YTD-76.57%
Dividend Est.- P/FCF- EPS past 5Y-21.09% ROI-230.40% 52W High-85.31% Beta1.24
Dividend TTM- Quick Ratio2.11 Sales past 5Y0.00% Gross Margin- 52W Low27.50% ATR (14)0.04
Dividend Ex-Date- Current Ratio2.11 EPS Y/Y TTM-23.90% Oper. Margin- RSI (14)47.71 Volatility8.21% 9.63%
Employees28 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price7.50
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q-10.62% Payout- Rel Volume0.43 Prev Close0.46
Sales Surprise- EPS Surprise-27.10% Sales Q/Q- EarningsNov 13 BMO Avg Volume1.45M Price0.43
SMA20-1.41% SMA50-6.17% SMA200-66.48% Trades Volume617,820 Change-5.29%
Date Action Analyst Rating Change Price Target Change
Jul-30-24Downgrade Cantor Fitzgerald Overweight → Neutral
Nov-03-21Initiated Oppenheimer Outperform $22
Nov-03-21Initiated B. Riley Securities Buy $27
Nov-28-24 09:55AM
Nov-26-24 07:40AM
07:30AM
Nov-25-24 07:30AM
Nov-15-24 08:35AM
07:30AM Loading…
Nov-13-24 07:30AM
Nov-12-24 08:35AM
07:30AM
Oct-31-24 04:15PM
Oct-29-24 12:55PM
Oct-23-24 07:30AM
Oct-22-24 07:30AM
Oct-09-24 05:37PM
Oct-02-24 07:30AM
Oct-01-24 07:30AM
07:30AM Loading…
Sep-03-24 07:30AM
Aug-22-24 07:31AM
Aug-08-24 07:00AM
Aug-05-24 07:30AM
Jul-30-24 06:32AM
Jul-29-24 11:58AM
07:00AM
Jul-26-24 04:11PM
Jul-02-24 07:30AM
May-21-24 07:30AM
May-07-24 01:53PM
07:30AM
Apr-29-24 07:30AM
Apr-22-24 07:30AM
Apr-02-24 07:30AM
07:30AM Loading…
Apr-01-24 07:30AM
Mar-27-24 09:31AM
01:13AM
Mar-26-24 11:53AM
07:00AM
Mar-15-24 07:30AM
Mar-14-24 04:05PM
Mar-11-24 08:16PM
04:05PM
Mar-06-24 07:30AM
Feb-26-24 07:30AM
Feb-06-24 08:47AM
Jan-04-24 07:30AM
Nov-16-23 07:30AM
Nov-15-23 07:30AM
Nov-07-23 07:30AM
Nov-03-23 06:00AM
Nov-02-23 07:30AM
Oct-27-23 07:30AM
Oct-24-23 04:30PM
Oct-16-23 07:30AM
Sep-07-23 07:45AM
Aug-30-23 08:00AM
Aug-09-23 09:09AM
Aug-08-23 09:52PM
07:00AM
Aug-02-23 07:30AM
Jul-11-23 07:30AM
Jul-05-23 07:30AM
Jun-28-23 07:00AM
Jun-27-23 07:17PM
Jun-20-23 07:30AM
Jun-02-23 07:30AM
May-23-23 09:40AM
07:30AM
May-18-23 03:53PM
07:30AM
May-04-23 04:05PM
May-01-23 07:30AM
Apr-19-23 07:30AM
Apr-12-23 07:30AM
Mar-28-23 07:30AM
Mar-27-23 08:00AM
07:12AM
Mar-23-23 11:03PM
07:30AM
Mar-21-23 08:00AM
Mar-16-23 12:18PM
07:30AM
Mar-15-23 07:30AM
Mar-07-23 08:00AM
Feb-22-23 08:00AM
Feb-21-23 07:30AM
Feb-20-23 08:50AM
Feb-09-23 08:00AM
Dec-22-22 08:00AM
Dec-21-22 04:05PM
Dec-15-22 08:00AM
Dec-01-22 08:38AM
07:30AM
Nov-28-22 08:00AM
Nov-21-22 08:00AM
Nov-15-22 12:55PM
Nov-14-22 08:00AM
Nov-10-22 08:00AM
Oct-12-22 08:00AM
Oct-11-22 08:00AM
Sep-29-22 07:30AM
Sep-27-22 07:32AM
Sep-06-22 07:32AM
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ricciardi LisaCEO & PresidentMar 14 '24Buy1.755,7009,975291,345Mar 14 04:34 PM